JP2001506611A5 - - Google Patents

Download PDF

Info

Publication number
JP2001506611A5
JP2001506611A5 JP1998525844A JP52584498A JP2001506611A5 JP 2001506611 A5 JP2001506611 A5 JP 2001506611A5 JP 1998525844 A JP1998525844 A JP 1998525844A JP 52584498 A JP52584498 A JP 52584498A JP 2001506611 A5 JP2001506611 A5 JP 2001506611A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998525844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001506611A (ja
Filing date
Publication date
Priority claimed from US08/759,788 external-priority patent/US5703098A/en
Application filed filed Critical
Publication of JP2001506611A publication Critical patent/JP2001506611A/ja
Publication of JP2001506611A5 publication Critical patent/JP2001506611A5/ja
Ceased legal-status Critical Current

Links

JP52584498A 1996-12-03 1997-12-03 新規免疫治療用のイミド/アミド類 Ceased JP2001506611A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/759,788 1996-12-03
US08/759,788 US5703098A (en) 1994-12-30 1996-12-03 Immunotherapeutic imides/amides
PCT/US1997/022369 WO1998024763A2 (en) 1996-12-03 1997-12-03 Immunotherapeutic imides/amides as pde iv and tnf inhibitors

Publications (2)

Publication Number Publication Date
JP2001506611A JP2001506611A (ja) 2001-05-22
JP2001506611A5 true JP2001506611A5 (https=) 2005-08-11

Family

ID=25056962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52584498A Ceased JP2001506611A (ja) 1996-12-03 1997-12-03 新規免疫治療用のイミド/アミド類

Country Status (13)

Country Link
US (1) US5703098A (https=)
EP (1) EP0942902A2 (https=)
JP (1) JP2001506611A (https=)
KR (1) KR20000069374A (https=)
CN (1) CN100372836C (https=)
AU (1) AU735540B2 (https=)
CA (1) CA2273002A1 (https=)
FI (1) FI991187A7 (https=)
HU (1) HUP0000232A3 (https=)
NZ (1) NZ336713A (https=)
RU (1) RU2177471C2 (https=)
SK (1) SK73299A3 (https=)
WO (1) WO1998024763A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
AU7449698A (en) * 1997-05-21 1998-12-11 Medion Research Laboratories Inc. Therapeutic agents for respiratory diseases
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
EP1496878A4 (en) * 2002-04-12 2007-12-26 Celgene Corp TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP2005522215A (ja) * 2002-04-12 2005-07-28 セルジーン・コーポレーション 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用
EP2258363A1 (en) 2002-05-17 2010-12-08 Celgene Corporation Compositions for treatment of cancers
CN1713905A (zh) * 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
TW200501945A (en) 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
EP1581205A1 (en) * 2002-11-18 2005-10-05 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US7153824B2 (en) * 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20060004043A1 (en) 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
JP2011515469A (ja) * 2008-03-24 2011-05-19 セルジーン コーポレイション シクロプロピル−n−{2−[(1s)−1−(3−エトキシ−4−メトキシフェニル)−2−(メチルスルホニル)エチル]−3−オキソイソインドリン−4−イル}カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
EP2395995A1 (en) 2009-02-10 2011-12-21 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
ES2451350T3 (es) * 2009-10-09 2014-03-26 Celgene Corporation Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
EP2583098B1 (en) 2010-06-15 2018-08-08 Celgene Corporation Biomarkers for the treatment of psoriasis
EP2601950A1 (en) * 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628425B1 (fr) * 1988-03-08 1992-04-03 Rhone Poulenc Sante Derives d'isoindolinone, leurs procedes de preparation et les medicaments les contenant
RU2015966C1 (ru) * 1991-06-27 1994-07-15 Киевский университет им.Т.Г.Шевченко Способ получения алкил-(не)замещенных 2-[4-(1-оксо-2-изоиндолинил)фенил]уксусных кислот или их нитрилов
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles

Similar Documents

Publication Publication Date Title
JP2000502280A5 (https=)
JP2000501771A5 (https=)
JP2000501599A5 (https=)
JP2000501018A5 (https=)
JP2000500076A5 (https=)
JP2000501324A5 (https=)
JP2000500055A5 (https=)
JP2000500026A5 (https=)
JP2000502472A5 (https=)
JP2000501825A5 (https=)
JP2000501338A5 (https=)
JP2000500874A5 (https=)
JP2001506611A5 (https=)
JP2000502425A5 (https=)
JP2000502568A5 (https=)
JP2000501774A5 (https=)
JP2000500912A5 (https=)
JP2000502570A5 (https=)
JP2000501876A5 (https=)
JP2000501744A5 (https=)
JP2000501229A5 (https=)
JP2000502316A5 (https=)
JP2000500857A5 (https=)
JP2000502714A5 (https=)
JP2000501569A5 (https=)